CT 1190B
Alternative Names: CT-1190BLatest Information Update: 10 Nov 2025
At a glance
- Originator CARsgen
- Class CAR-T cell therapies; Gene therapies; Skin disorder therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Systemic lupus erythematosus; Systemic scleroderma
Most Recent Events
- 10 Nov 2025 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Non-Hodgkin's lymphoma released by CARsgen Therapeutics
- 11 Jul 2025 Tongji Hospital plans a phase I trial for B-Cell Non-Hodgkin Lymphoma (Second-line therapy or greater) in China (Parenteral, Infusion) in July 2025 (NCT07053670)
- 09 Jul 2025 CARsgen Therapeutics initiates phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (Infusion) (NCT07053670)